Cargando…
Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose
INTRODUCTION: Pridopidine is a highly selective sigma-1 receptor (S1R) agonist in development for the treatment of Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS). Pridopidine’s activation of S1R enhances cellular processes that are crucial for neuronal function and survival but ar...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043059/ https://www.ncbi.nlm.nih.gov/pubmed/36811812 http://dx.doi.org/10.1007/s40120-023-00449-w |